Abstract
A challenge paradigm was designed to test the functional sensitivity to anticholinergic agents in Alzheimer's disease. Ten patients with dementia of the Alzheimer type were serially administered three different intravenous doses of the centrally active anticholinergic drug scopolamine and placebo. Testing was carried out in a placebo-controlled, double-blind fashion to measure cognitive, physiologic and behavioral changes. Alzheimer patients showed a marked, dose-related behavioral and cognitive sensitivity to temporary cholinergic blockade. Scopolamine testing may serve as an index of the status of central cholinergic functional integrity, and ultimately may prove useful as a diagnostic or staging test in the evaluation of the cholinergic system in dementia. Research is currently under way with elderly age-matched controls and populations with other neuropsychiatric disorders to explore this hypothesis further.
This is a preview of subscription content, log in via an institution to check access.
References
Bartus RT (1978) Evidence for a direct cholinergic involvement in the scopolamine induced amnesia in monkey: Effect of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 9:833–836
Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis in geriatric memory dysfunction. Science 217:408–417
Brinkman SD, Pomara N, Goodnick PJ, Barnett N, Domino EF (1982) A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). J Clin Psychopharmacol 2:281–285
Buschke H (1973) Selective reminding for analysis of memory and learning. J Verb Learn Verb Beh 12:543–550
Cohen RM, Cohen MR, Weingartner H, Pickar D, Murphy DL (1983) High-dose naloxone affects task performance in normal subjects. Psychiatr Res 8:127–136
Drachman DA (1974) Human memory and the cholinergic system. Arch Neurol 30:113–121
Ferris SH, Sathananthan G, Riesberg B, Gershon S (1979) Longterm choline treatment of memory-impaired elderly patients. Science 205:1039–1040
Janowsky DS, El-Yousef MK, Davis JM, Scherke HJ (1978) Cholinergic antagonism of manic symptoms. Lancet i:1236
Safer DJ, Allen RP (1971) The central effects of scopolamine in man. Biol Psychiatr 14:347–355
Sitaram N, Weingartner H, Gillin JC (1978) Human serial learning: Enhancement with arecholine and choline and impairment with scopolamine. Science 201:274–276
Weingartner H, Kaye W, Smallberg SA, Ebert MH, Gillin JC, Sitaram N (1981) Memory failures in progressive idiopathic dementia. J Abnorm Psychol 90:187–196
Wells CE (1979) Pseudodementia. Am J Psychiatry 136:895–900
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, De-Long MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215:1237–1239
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sunderland, T., Tariot, P., Murphy, D.L. et al. Scopolamine challenges in Alzheimer's disease. Psychopharmacology 87, 247–249 (1985). https://doi.org/10.1007/BF00431817
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00431817